Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
547.03
-0.86 (-0.16%)
At close: Nov 11, 2026, 4:00 PM EST
542.94
-4.09 (-0.75%)
After-hours: Nov 11, 2026, 7:51 PM EST

Vertex Pharmaceuticals Revenue

Vertex Pharmaceuticals had revenue of $3.44B in the quarter ending September 30, 2026, with 11.85% growth. This brings the company's total for the last twelve months to $12.95B, up 10.48% year-over-year. In the year 2025, Vertex Pharmaceuticals had annual revenue of $12.00B with 8.90% growth. That makes Vertex Pharmaceuticals the 1,185th largest company in the world by revenue and 386th in the United States.

Revenue (ttm)
$12.95B
Revenue Growth
+10.48%
P/S Ratio
10.71
Revenue / Employee
$2,023,688
Employees
6,400
Market Cap
138.69B

Revenue Chart

Revenue by Segment

By Segment

Chart
  • Trikafta / Kaftrio 10.31B 85.9%
  • Alyftrek 837.80M 7.0%
  • Other 644.70M 5.4%
  • Casgevy 115.80M 1.0%
  • Journavx 59.60M 0.5%
  • Other Collaborative and Royalty 30.70M 0.3%

By Geography

Chart
  • United States Product 7.55B 62.7%
  • Outside of United States Product 4.45B 37.0%
  • Other Collaborative and Royalty 30.70M 0.3%
Fiscal year ended Dec 31, 2025 See the full Vertex Pharmaceuticals breakdown

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202512.00B981.20M8.90%
Dec 31, 202411.02B1.15B11.66%
Dec 31, 20239.87B938.50M10.51%
Dec 31, 20228.93B1.36B17.91%
Dec 31, 20217.57B1.37B22.06%
Dec 31, 20206.21B2.04B49.08%
Dec 31, 20194.16B1.12B36.59%
Dec 31, 20183.05B558.95M22.46%
Dec 31, 20172.49B786.48M46.20%
Dec 31, 20161.70B669.84M64.89%
Dec 31, 20151.03B451.92M77.86%
Dec 31, 2014580.42M-631.56M-52.11%
Dec 31, 20131.21B-315.07M-20.63%
Dec 31, 20121.53B116.42M8.25%
Dec 31, 20111.41B1.27B883.91%
Dec 31, 2010143.37M41.48M40.71%
Dec 31, 2009101.89M-73.62M-41.94%
Dec 31, 2008175.50M-23.51M-11.81%
Dec 31, 2007199.01M-17.34M-8.02%
Dec 31, 2006216.36M55.47M34.47%
Dec 31, 2005160.89M--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Regeneron Pharmaceuticals16.90B
BeOne Medicines AG6.45B
Incyte6.01B
argenx SE5.92B
Genmab4.30B
BioNTech SE2.75B
Royalty Pharma2.62B
Moderna2.53B
Revenue Rankings